{"id":"https://openalex.org/W2228067035","doi":"https://doi.org/10.1200/jco.2005.23.16_suppl.8529","title":"Phase I trial of the epothilone B analog BMS-247550 (ixabepilone) in children with refractory solid tumors","display_name":"Phase I trial of the epothilone B analog BMS-247550 (ixabepilone) in children with refractory solid tumors","publication_year":2005,"publication_date":"2005-06-01","ids":{"openalex":"https://openalex.org/W2228067035","doi":"https://doi.org/10.1200/jco.2005.23.16_suppl.8529","mag":"2228067035"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2005.23.16_suppl.8529","doi":"https://doi.org/10.1200/jco.2005.23.16_suppl.8529","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2005.23.16_suppl.8529","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5071679104","display_name":"Brigitte C. Widemann","orcid":"https://orcid.org/0000-0002-9198-7175","observed_orcids":["https://orcid.org/0000-0002-9198-7175"]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]},{"id":"https://openalex.org/I4210140884","display_name":"National Cancer Institute","ror":"https://ror.org/040gcmg81","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I4210140884"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"B. C. Widemann","raw_affiliation_strings":["National Cancer Inst, Bethesda, MD; Bristol-Myers Squibb, Princeton, NJ"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"National Cancer Inst, Bethesda, MD; Bristol-Myers Squibb, Princeton, NJ","institution_ids":["https://openalex.org/I4210091812","https://openalex.org/I4210140884"]}]},{"author_position":"middle","author":{"id":null,"display_name":"E. Fox","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]},{"id":"https://openalex.org/I4210140884","display_name":"National Cancer Institute","ror":"https://ror.org/040gcmg81","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I4210140884"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"E. Fox","raw_affiliation_strings":["National Cancer Inst, Bethesda, MD; Bristol-Myers Squibb, Princeton, NJ"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"National Cancer Inst, Bethesda, MD; Bristol-Myers Squibb, Princeton, NJ","institution_ids":["https://openalex.org/I4210091812","https://openalex.org/I4210140884"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5090559168","display_name":"Wendy J. Goodspeed","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]},{"id":"https://openalex.org/I4210140884","display_name":"National Cancer Institute","ror":"https://ror.org/040gcmg81","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I4210140884"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"W. J. Goodspeed","raw_affiliation_strings":["National Cancer Inst, Bethesda, MD; Bristol-Myers Squibb, Princeton, NJ"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"National Cancer Inst, Bethesda, MD; Bristol-Myers Squibb, Princeton, NJ","institution_ids":["https://openalex.org/I4210091812","https://openalex.org/I4210140884"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5012188951","display_name":"Anne Goodwin","orcid":"https://orcid.org/0000-0001-9336-5399","observed_orcids":["https://orcid.org/0000-0001-9336-5399"]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]},{"id":"https://openalex.org/I4210140884","display_name":"National Cancer Institute","ror":"https://ror.org/040gcmg81","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I4210140884"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"A. Goodwin","raw_affiliation_strings":["National Cancer Inst, Bethesda, MD; Bristol-Myers Squibb, Princeton, NJ"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"National Cancer Inst, Bethesda, MD; Bristol-Myers Squibb, Princeton, NJ","institution_ids":["https://openalex.org/I4210091812","https://openalex.org/I4210140884"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109307559","display_name":"M. Cohen","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]},{"id":"https://openalex.org/I4210140884","display_name":"National Cancer Institute","ror":"https://ror.org/040gcmg81","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I4210140884"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"M. Cohen","raw_affiliation_strings":["National Cancer Inst, Bethesda, MD; Bristol-Myers Squibb, Princeton, NJ"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"National Cancer Inst, Bethesda, MD; Bristol-Myers Squibb, Princeton, NJ","institution_ids":["https://openalex.org/I4210091812","https://openalex.org/I4210140884"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5006092876","display_name":"Tito Fojo","orcid":"https://orcid.org/0000-0002-8083-2688","observed_orcids":["https://orcid.org/0000-0002-8083-2688","https://orcid.org/0000-0001-9209-8831"]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]},{"id":"https://openalex.org/I4210140884","display_name":"National Cancer Institute","ror":"https://ror.org/040gcmg81","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I4210140884"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"T. Fojo","raw_affiliation_strings":["National Cancer Inst, Bethesda, MD; Bristol-Myers Squibb, Princeton, NJ"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"National Cancer Inst, Bethesda, MD; Bristol-Myers Squibb, Princeton, NJ","institution_ids":["https://openalex.org/I4210091812","https://openalex.org/I4210140884"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5069613777","display_name":"Alexander Dimitrios Colevas","orcid":"https://orcid.org/0000-0003-3849-4264","observed_orcids":["https://orcid.org/0000-0003-3849-4264"]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]},{"id":"https://openalex.org/I4210140884","display_name":"National Cancer Institute","ror":"https://ror.org/040gcmg81","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I4210140884"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"A. D. Colevas","raw_affiliation_strings":["National Cancer Inst, Bethesda, MD; Bristol-Myers Squibb, Princeton, NJ"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"National Cancer Inst, Bethesda, MD; Bristol-Myers Squibb, Princeton, NJ","institution_ids":["https://openalex.org/I4210091812","https://openalex.org/I4210140884"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5024249524","display_name":"Frank M. Balis","orcid":"https://orcid.org/0000-0002-8117-6926","observed_orcids":["https://orcid.org/0000-0002-8117-6926"]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]},{"id":"https://openalex.org/I4210140884","display_name":"National Cancer Institute","ror":"https://ror.org/040gcmg81","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I4210140884"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"F. M. Balis","raw_affiliation_strings":["National Cancer Inst, Bethesda, MD; Bristol-Myers Squibb, Princeton, NJ"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"National Cancer Inst, Bethesda, MD; Bristol-Myers Squibb, Princeton, NJ","institution_ids":["https://openalex.org/I4210091812","https://openalex.org/I4210140884"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":6,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"23","issue":"16_suppl","first_page":"8529","last_page":"8529"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11752","display_name":"Cancer Treatment and Pharmacology","score":0.9634000062942505,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11752","display_name":"Cancer Treatment and Pharmacology","score":0.9634000062942505,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10492","display_name":"Microtubule and mitosis dynamics","score":0.007799999788403511,"subfield":{"id":"https://openalex.org/subfields/1307","display_name":"Cell Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10253","display_name":"Sarcoma Diagnosis and Treatment","score":0.00559999980032444,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/ixabepilone","display_name":"ixabepilone","score":0.9980000257492065},{"id":"https://openalex.org/keywords/epothilone-b-analog","display_name":"epothilone B analog","score":0.984000027179718},{"id":"https://openalex.org/keywords/pediatric-solid-tumors","display_name":"pediatric solid tumors","score":0.8519999980926514},{"id":"https://openalex.org/keywords/refractory-cancer","display_name":"refractory cancer","score":0.8830000162124634},{"id":"https://openalex.org/keywords/dose-limiting-toxicity","display_name":"dose-limiting toxicity","score":0.878000020980835},{"id":"https://openalex.org/keywords/neutropenia","display_name":"neutropenia","score":0.9390000104904175},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.7879999876022339},{"id":"https://openalex.org/keywords/maximum-tolerated-dose","display_name":"maximum tolerated dose","score":0.8790000081062317},{"id":"https://openalex.org/keywords/osteosarcoma","display_name":"osteosarcoma","score":0.7289999723434448},{"id":"https://openalex.org/keywords/rhabdomyosarcoma","display_name":"rhabdomyosarcoma","score":0.9919999837875366},{"id":"https://openalex.org/keywords/wilms-tumor","display_name":"Wilms tumor","score":0.9860000014305115},{"id":"https://openalex.org/keywords/hepatoblastoma","display_name":"hepatoblastoma","score":0.9959999918937683},{"id":"https://openalex.org/keywords/sarcoma","display_name":"sarcoma","score":0.8989999890327454}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8517241477966309},{"id":"https://openalex.org/C2777063308","wikidata":"https://www.wikidata.org/wiki/Q1435822","display_name":"Neutropenia","level":3,"score":0.7845299243927002},{"id":"https://openalex.org/C2777511904","wikidata":"https://www.wikidata.org/wiki/Q425227","display_name":"Taxane","level":4,"score":0.6802215576171875},{"id":"https://openalex.org/C2777292972","wikidata":"https://www.wikidata.org/wiki/Q423762","display_name":"Paclitaxel","level":3,"score":0.5821983218193054},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.5803467035293579},{"id":"https://openalex.org/C2779194965","wikidata":"https://www.wikidata.org/wiki/Q11711607","display_name":"Ixabepilone","level":5,"score":0.5307630896568298},{"id":"https://openalex.org/C2780844630","wikidata":"https://www.wikidata.org/wiki/Q1898141","display_name":"Rhabdomyosarcoma","level":3,"score":0.5163532495498657},{"id":"https://openalex.org/C29730261","wikidata":"https://www.wikidata.org/wiki/Q274160","display_name":"Toxicity","level":2,"score":0.4967363476753235},{"id":"https://openalex.org/C142424586","wikidata":"https://www.wikidata.org/wiki/Q7307572","display_name":"Refractory (planetary science)","level":2,"score":0.4883575141429901},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.4773818850517273},{"id":"https://openalex.org/C2778850193","wikidata":"https://www.wikidata.org/wiki/Q3775974","display_name":"Febrile neutropenia","level":4,"score":0.43349239230155945},{"id":"https://openalex.org/C126894567","wikidata":"https://www.wikidata.org/wiki/Q105650","display_name":"Urology","level":1,"score":0.4183726906776428},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.4059833586215973},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.4043746590614319},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.3967812657356262},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.3914697766304016},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.3154568672180176},{"id":"https://openalex.org/C2778256501","wikidata":"https://www.wikidata.org/wiki/Q223911","display_name":"Sarcoma","level":2,"score":0.31431254744529724},{"id":"https://openalex.org/C2775930923","wikidata":"https://www.wikidata.org/wiki/Q12859063","display_name":"Metastatic breast cancer","level":4,"score":0.3135620057582855},{"id":"https://openalex.org/C530470458","wikidata":"https://www.wikidata.org/wiki/Q128581","display_name":"Breast cancer","level":3,"score":0.2751046419143677},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.08834818005561829},{"id":"https://openalex.org/C87355193","wikidata":"https://www.wikidata.org/wiki/Q411","display_name":"Astrobiology","level":1,"score":0.0},{"id":"https://openalex.org/C121332964","wikidata":"https://www.wikidata.org/wiki/Q413","display_name":"Physics","level":0,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2005.23.16_suppl.8529","doi":"https://doi.org/10.1200/jco.2005.23.16_suppl.8529","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2005.23.16_suppl.8529","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":1.0,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2240137614","https://openalex.org/W2123148157","https://openalex.org/W2146472326","https://openalex.org/W2062399327","https://openalex.org/W177209949","https://openalex.org/W2035908704","https://openalex.org/W2253499206","https://openalex.org/W2165708803","https://openalex.org/W2076811098","https://openalex.org/W2342241463"],"abstract_inverted_index":{"8529":[0],"Background:":[1],"The":[2,122,228,283],"epothilone":[3],"B":[4],"analog":[5],"ixabepilone":[6,112,288],"is":[7,233,312],"a":[8,47],"novel":[9],"non-taxane":[10],"microtubule":[11],"stabilizing":[12],"agent":[13],"with":[14,76,130,156,218],"in":[15,18,21,225,315],"vitro":[16],"and":[17,23,108,139,151,160,222,258,266,299],"vivo":[19],"activity":[20],"adult":[22,168,308,326],"pediatric":[24],"cancer":[25],"models":[26],"that":[27],"are":[28],"naturally":[29],"insensitive":[30],"to":[31,37,101,132,166,236,307],"paclitaxel":[32],"or":[33,183,190,331,334],"have":[34],"developed":[35],"resistance":[36],"paclitaxel.":[38],"In":[39],"adults,":[40],"the":[41,103,114,148,167,204,214,290,300,318,325],"maximum":[42],"tolerated":[43,314],"dose":[44,124,200,209,231],"(MTD)":[45],"on":[46,96,113,194,317],"daily":[48,115,169,319],"x":[49,116,170],"5":[50,117,171,211],"days":[51],"(d)":[52],"q":[53,119],"21d":[54,120],"schedule":[55,321],"was":[56,67,126,145,216],"6":[57,135,237],"mg/m2/d":[58,128],"IV":[59],"over":[60],"1":[61],"hour.":[62],"Dose":[63,158],"limiting":[64],"toxicity":[65,104],"(DLT)":[66],"neutropenia.":[68],"Methods:":[69],"Children":[70],"(median":[71],"age,":[72],"9.5yr;":[73],"range,":[74],"2\u201318yr),":[75],"refractory":[77],"solid":[78],"tumors":[79],"(osteosarcoma":[80],"n=2,":[81,83,86,88],"rhabdomyosarcoma":[82],"Wilms":[84],"tumor":[85],"hepatoblastoma":[87],"other":[89,92],"sarcoma":[90],"n=5,":[91],"n=3)":[93],"were":[94,154,164,197,305],"entered":[95],"this":[97],"phase":[98,173],"I":[99,174],"trial":[100],"determine":[102],"profile,":[105],"DLTs,":[106],"MTD,":[107],"pharmacokinetics":[109],"(PK)":[110],"of":[111,287,292],"d":[118,172],"schedule.":[121],"starting":[123],"level":[125,210,232],"3":[127],"(n=3),":[129,136,138],"escalations":[131],"4.5":[133],"(n=4),":[134],"8":[137,229],"10":[140],"(n=3)":[141],"mg/m2/d.":[142],"PK":[143,161],"sampling":[144,162],"performed":[146],"after":[147],"first":[149,205],"dose,":[150],"plasma":[152],"concentrations":[153],"assayed":[155],"LC/MS/MS.":[157],"levels":[159,201],"times":[163],"identical":[165],"trial.":[175],"Results:":[176],"No":[177],"DLTs":[178],"(grade":[179],"\u22653":[180],"non-hematologic":[181],"toxicity,":[182],"grade":[184,191],"4":[185,192],"neutropenia":[186,220,248],"for":[187,278],"\u22655":[188],"days,":[189],"thrombocytopenia":[193,267],"\u22652":[195,240],"days)":[196],"observed":[198],"at":[199,294,322],"1\u20134":[202],"during":[203,242],"treatment":[206],"cycle.":[207],"At":[208],"(10":[212],"mg/m2/d)":[213],"MTD":[215],"exceeded":[217],"dose-limiting":[219],"(n=1)":[221,224],"fatigue":[223,256],"2":[226,255,260],"patients.":[227,238],"mg/m2":[230],"being":[234],"expanded":[235],"Grade":[239],"non-DLTs":[241],"cycle":[243],"#1":[244],"included":[245],"gr.":[246,250,254,259],"3\u20134":[247],"(n=7),":[249],"2\u20133":[251],"anemia":[252],"(n=8),":[253],"(n=2),":[257],"constipation":[261],"(n=2).":[262],"Sensory":[263],"neuropathy":[264],"(n=4)":[265,268],"did":[269],"not":[270],"exceed":[271],"gr.1.":[272],"Five":[273],"patients":[274],"had":[275],"stable":[276],"disease":[277],"2\u201313":[279],"cycles":[280],"(median,":[281],"5).":[282],"mean":[284],"terminal":[285],"half-life":[286],"(14.8\u00b16h),":[289],"volume":[291],"distribution":[293],"steady":[295],"state":[296],"(352":[297],"L/m2),":[298],"clearance":[301],"(489":[302],"ml/min/m2)":[303],"(n=9),":[304],"similar":[306],"values.":[309],"Conclusions:":[310],"Ixabepilone":[311],"well":[313],"children":[316],"x5d":[320],"doses":[323],"exceeding":[324],"MTD.":[327],"Author":[328],"Disclosure":[329],"Employment":[330],"Leadership":[332],"Consultant":[333],"Advisory":[335],"Role":[336],"Stock":[337],"Ownership":[338],"Honoraria":[339],"Research":[340],"Funding":[341],"Expert":[342],"Testimony":[343],"Other":[344],"Remuneration":[345],"Bristol-Myers":[346],"Squibb":[347]},"counts_by_year":[],"updated_date":"2026-10-14T16:39:01.820549","created_date":"2016-06-24T00:00:00"}